NOTICE: Due to a lapse in annual appropriations, most of this website is not being updated. Learn more.
Form submissions will still be accepted but will not receive responses at this time. Sections of this site for programs using non-appropriated funds (such as NVLAP) or those that are excepted from the shutdown (such as CHIPS and NVD) will continue to be updated.
An official website of the United States government
Here’s how you know
Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Translating stem cell research from the bench to the clinic: A need for better quality data
Published
Author(s)
Anne L. Plant, graham C. parker
Abstract
A new generation of cell therapies shows great medical promise, but few new products have made it into the marketplace. The technical challenges associated with the application of stem and other cells for therapies are paralleled by the challenges associated with investment funding and regulatory approval. Regulators and investors appear to be voicing similar concerns: they see 1) an insufficient amount of high quality data that provide confidence regarding the claims of medical benefit, 2) an insufficient understanding of the mechanism of action, and 3) a lack of identification of essential characteristics for product release criteria and for assuring reproducibility in manufacturing. The ensuing frustration on the part of researchers and developers may be the result of failure to fully comprehend what is required to assure that confidence.
Plant, A.
and parker, G.
(2013),
Translating stem cell research from the bench to the clinic: A need for better quality data, Stem Cells and Development, [online], https://doi.org/10.1089/scd.2013.0188
(Accessed October 14, 2025)